Stockhub

Lineage Cell Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

14 August 2022

13 August 2022

29 July 2022

  • curprev 23:2623:26, 29 July 2022 >Chris 1,196 bytes +1,196 Created page with "Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial f..."
Retrieved from "https://stockhub.co/research/Lineage_Cell_Therapeutics,_Inc."